Skip to main content
SpringerLink
Log in
Book cover

Cholinesterases and Anticholinesterase Agents pp 1028–1050Cite as

Therapy of Myasthenia Gravis

  • Chapter

  • 238 Accesses

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 15))

Abstract

Myasthenia gravis is a chronic disease characterized by weakness and abnormal fatigability of skeletal muscle. The muscles innervated by the cranial nerves are particularly affected, and usually those of the neck, trunk, and extremities. In severe cases, weakness of the muscles of respiration occurs. Smooth and cardiac muscles are not involved. The disease usually becomes generalized, but in a minority of cases it remains localized to the extraocular muscles. The symptoms are commonly ameliorated, although to a variable degree, by anti-cholinesterase (anti-ChE) compounds. This response serves as the basis for diagnosis and management of the disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature

  • Akao, S., and H. Kawaishi: Case of myasthenia gravis cured by partial parathyroidectomy. Rinshö-Naika Shönika 7, 281 (1952).

    Google Scholar 

  • Anderson, H. J., C. H. Churchill-Davidson and A. T. Richardson: Bronchial neoplasm with myasthenia: Prolonged apnoea after administration of succinylcholine. Lancet 1953 II, 1291.

    Article  Google Scholar 

  • Aranow, H. jr., P. F. A. Hoefer and L. P. Rowland: The long-acting anticholinesterase drugs in the management of myasthenia gravis. J. chron. Dis. 6, 113–125 (1958).

    Google Scholar 

  • Bergh, N. P.: Reaction of patients with myasthenia gravis to different agents causing neuromuscular block. Scand. J. clin. Lab. Invest. 5, 11 (1953).

    Google Scholar 

  • Bergh, N. P.: Thymectomy in Treatment of myasthenia gravis. Acta chir. scand. (Suppl.) 1753, 1 (1953).

    Google Scholar 

  • Bickerstaff, E. R., and A. L. Woolf: The intramuscular nerve endings in myasthenia gravis. Brain 83, 10–23 (1960).

    Article  PubMed  CAS  Google Scholar 

  • Blalock, A., A. M. Harvey, F. R. Ford and J. L. Lilienthal jr.: The treatment of myasthenia gravis by removal of the thymus gland. J. Amer. med. Ass. 117, 1529 (1941).

    Article  Google Scholar 

  • Botelho, S. Y.: Alterations in muscle tension without similar changes in electrical activity in patients with myasthenia gravis. J. clin. Invest. 34, 1403 (1955a).

    Article  PubMed  CAS  Google Scholar 

  • Bergh, N. P.: Comparison of simultaneously recorded electrical and mechanical activity in myasthenia gravis patients and in partially curarized normal humans. Amer. J. Med. 19, 693 (1955 b).

    Google Scholar 

  • Brooks, V. B.: The action of botulinum toxin on motor nerve filaments. J. Physiol. (Lond.) 123, 501 (1954).

    CAS  Google Scholar 

  • Burns, B. D., and W. D. M. Paton: Depolarization of the motor end-plate by decamethonium and acetylcholine. J. Physiol. (Lond.) 115, 41 (1951).

    CAS  Google Scholar 

  • Churchill-Davidson, H. C., and A. T. Richardson: Neuromuscular transmission in myasthenia gravis. J. Physiol. (Lond.) 122, 252–263 (1953).

    CAS  Google Scholar 

  • Coers, C., and J. E. Desmedt: Evidence for characteristic malformation of the neuromuscular junction in myasthenia gravis. Acta neurol. belg. 59, 539–561 (1959).

    CAS  Google Scholar 

  • Comroe, J. H. Jr., J. Todd, G. D. Gammon, I. H. Leopold, G. B. Koelle, O. Bodansky and A. Gilman: The effect of di-isopropyl-fluorophosphate (DFP) upon patients with myasthenia gravis. Amer. J. med. Sei. 212, 641–651 (1946).

    Article  CAS  Google Scholar 

  • Desmedt, J. E.: Neurochemical lesion in myasthenia gravis. Fed. Proc. 18, 36 (1959).

    Google Scholar 

  • Dulce, N. J.: Behandlung der myasthenia gravis und psychischer Störungen bei der Chorea minor mit Glutaminsäure. Münch, med. Wschr. 96, 1235 (1954).

    CAS  Google Scholar 

  • Dunlop, D. M.: Thymectomy in myasthenia gravis. Trans, med. chir. Soc. Edinb. 132, 59 (1953).

    Google Scholar 

  • Eaton, L. M., O. P. Clagett and J. A. Bastron: Thymus and its relationship to diseases of nervous system. Study of 374 cases of myasthenia gravis and comparison of 87 patients undergoing thymectomy with 225 controls. A. Res. Nerv. a. Ment. Dis., Proc. 32, 107 (1953).

    CAS  Google Scholar 

  • Elam, J. O., D. G. Green, M. A. Schneider, H. M. Ruben, A. S. Gordon, R. F. Hustead, D. W. Benson, J. A. Clements and A. Ruben: Head-tilt method of oral resuscitation. J. Amer. med. Ass. 173, 812–815 (1960).

    Google Scholar 

  • Elam, J. O., D. G. Green, E. S. Brown and J. A. Clements: Oxygen and carbon dioxide exchange and energy cost of expired air resuscitation. J. Amer. med. Ass. 167, 328–334 (1958).

    Article  CAS  Google Scholar 

  • Fatt, P.: Biophysics of junctional transmission. Physiol. Rev. 34, 674 (1954).

    PubMed  CAS  Google Scholar 

  • Ferguson, F. R., E. C. Hutchinson and L. A. Liversedge: Myasthenia gravis; Results of medical management. Lancet 1955 II, 636.

    Article  Google Scholar 

  • Granirer, L. W.: Beneficial effect of postpartum plasma in a case of myasthenia gravis. Conn. med. J. 172, 934 (1953).

    Google Scholar 

  • Grob, D.: Course and management of myasthenia gravis. J. Amer. med. Ass. 153, 529 (1953).

    Article  CAS  Google Scholar 

  • Grob, D.: Effect of Sarin in patients with myasthenia gravis. Progress Report to U.S. Army Chemical Corps Medical Laboratories, Army Chemical Center, Med. (1955).

    Google Scholar 

  • Grob, D.: The manifestations and treatment of poisoning due to nerve gas and other organic phosphorus anticholinesterase compounds. Arch, intern. Med. 98, 221–239 (1956).

    CAS  Google Scholar 

  • Grob, D.: The neuromuscular system. Chapter 30 in Clinical Physiology. 725–756. Ed. by Arthur Grollman. New York: McGraw-Hill Inc. 1957.

    Google Scholar 

  • Grob, D.: Myasthenia gravis: Current status of pathogenesis, clinical manifestations and management. J. chron. Dis. 8, 536–566 (1958).

    Article  PubMed  CAS  Google Scholar 

  • Grob, D., and A. M. Harvey: Observations on the effects of tetraethyl pyrophosphate (TEPP) in man and on its use in the treatment of myasthenia gravis. Bull. Johns Hopk. Hosp. 84, 533–567 (1949).

    Google Scholar 

  • Grob, D., and A. M. Harvey: Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. Bull. Johns Hopk. Hosp. 91, 124–136 (1952).

    CAS  Google Scholar 

  • Grob, D., and A. M. Harvey: Abnormalities in neuromuscular transmission, with special reference to myasthenia gravis. Amer. J. Med. 15, 695–709 (1953).

    Article  PubMed  CAS  Google Scholar 

  • Grob, D., and R. J. Johns: Use of oximes in the treatment of intoxication by anticholinesterase compounds in patients with myasthenia gravis. Amer. J. Med. 24, 512–518 (1958 a).

    Google Scholar 

  • Grob, D., and R. J. Johns: Treatment of anticholinesterase intoxication in normal subjects and myasthenia patients with oximes. J. Amer. med. Ass. 166, 1855–1858 (1958b).

    Article  CAS  Google Scholar 

  • Grob, D., and R. J. Johns: Use of the oxime 1,1 ’-trimethylene bis-(4-formylpyridinium bromide) dioxime (EA1814, TMB-4) in the management of intoxication by anticholinesterase compounds. Contractor’s Progress Report to U.S. Army Chemical Corps. Medical Laboratories, Army Chemical Center, Md., August (1958c).

    Google Scholar 

  • Furtherstudies on the mechanism of the defect in neuromuscular transmission in myasthenia gravis, with particular reference to the acetylcholine-insensitive block. In H. R. Viets, ed., Myasthenia Gravis: Second Internat. Sympos. Proc. 127–149. Springfield, 111.: Chas. C. Thomas 1961.

    Google Scholar 

  • M. Harvey: Studies in neuromuscular function. I. Introduction and methods. Bull. Johns Hop. Hosp. 99, 115–124 (1956a).

    Google Scholar 

  • M. Harvey: Studies in neuromuscular function. III. Stimulating and depressant effects of acetylcholine and choline in normal subjects. Bull. Johns Hopk. Hosp. 99, 136–152 (1956b).

    Google Scholar 

  • M. Harvey: Studies in neuromuscular function. IV. Stimulating and depressant effects of acetylcholine and choline in patients with myasthenia gravis, and their relationship to the defect in neuromuscular transmission. Bull. Johns Hopk. Hosp. 99, 153–181 (1956c). Studies in neuromuscular function.

    Google Scholar 

  • M. Harvey: Effects of anticholinesterase compounds, d-tubocurarine, and decamethonium in normal subjects. Bull. Johns Hopk. Hosp. 99, 195 (1956 d).

    Google Scholar 

  • M. Harvey: Studies in neuromuscular function. VI: Effects of anticholinesterase compounds, d-tubocurarine, and decamethonium in patients with myasthenia gravis. Bull. Johns Hopk. Hosp. 99, 219–238 (1956e).

    Google Scholar 

  • M. Harvey: Alterations in neuromuscular transmission in myasthenia gravis, as determined by studies of drug action. Amer. J. Med. 19, 684–690 (1955).

    Article  PubMed  Google Scholar 

  • M. Harvey: A. Liljestrand and R. J. Johns: Potassium movement in normal subjects and in patients with familial periodic paralysis. A.er. J. Med. 23, 340–375 (1957).

    Google Scholar 

  • M. Harvey, and K. E. Osserman: Unpublished observations (1958).

    Google Scholar 

  • Harvey, A. M., and J. L. Lilienthal: Observations on the nature of myasthenia gravis. The intra-arterial injection of acetylcholine, prostigmine and adrenaline. Bull. Johns Hopk. Hosp. 69, 566 (1941).

    CAS  Google Scholar 

  • Harvay, A. M., J. L. Lilienthal Jr., D. Grob, B. F. Jones and S. A. Talbot: The administration of di-isopropyl fluorophosphate to man: IV. The effects on neuromuscular function in normal subjects and in myasthenia gravis. Bull. Johns Hopk. Hosp. 81, 267–292 (1947).

    Google Scholar 

  • S. A. Talbot: Observations on the nature of myasthenia gravis. The effect of thymectomy on neuromuscular transmission. J. clin. Invest. 21, 579 (1942).

    Google Scholar 

  • Harvay, A. M., and R. L. Masland: The electromyogram in myasthenia gravis. Bull. Johns Hopk. Hosp. 69, 1 (1941).

    Google Scholar 

  • Harvay, A. M., and M. R. Whitehill: Prostigmine as aid in diagnosis of myasthenia gravis. J. Amer. med. Ass. 108, 1329 (1937).

    Article  Google Scholar 

  • Harvay, A. M., Quinine as adjuvant to prostigmine in diagnosis of myasthenia gravis. Preliminary report. Bull. Johns Hopk. Hosp. 61, 216 (1937).

    Google Scholar 

  • Herzfeld, E., O. Kraupp, K. Pateisky u. C. Stumpf: Pharmakologische und klinische Wirkungen des Cholinesterashemmkörpers Hexamethylen-bis-(N-methyl-carbaminoyl-l-me-thyl-3-oxypyridiniumbromid) (BC 51) (Pharmacological and clinical effects of the cholinesterase inhibitor hexamethylene-bis-(N-methylcarbaminoyl-l-methyl-3-oxypyridinium bromide) (BC 51). Wien. kin. Wschr. 69, 245–248 (1957).

    CAS  Google Scholar 

  • Hoefer, P. F. A., H. Aronow and L. P. Rowland: Therapy of myasthenia gravis. Neurology 3, 691 (1953).

    Article  PubMed  CAS  Google Scholar 

  • Hutter, O. F.: Effect of choline on neuromuscular transmission in the cat. J. Physiol. (Lond.) 117, 241 (1952).

    CAS  Google Scholar 

  • Irwin, R. U., and M. J. Smith III: Cholinesterase inhibition by galanthamine and lycoramine. Biochem. Pharmacol. 3, 147–148 (1960).

    Article  PubMed  CAS  Google Scholar 

  • Johns, R. J.: Factors influencing muscle membrane potential in man, as recorded with intracellular microelectrodes. J. Pharmacol, exp. Ther. 122, 36a (1958).

    Google Scholar 

  • Johns, R. J., D. Grob and A. M. Harvey: Electromyographic changes in myasthenia gravis. Amer. J. Med. 19, 679–683 (1955).

    Article  PubMed  CAS  Google Scholar 

  • Johns, R. J.: Studies in neuromuscular function. II. Effects of nerve stimulation in normal subjects and in patients with myasthenia gravis. Bull. Johns Hopk. Hosp. 99, 125–135 (1956).

    CAS  Google Scholar 

  • Jorgensen, J. B., and F. Therkelsen: Thymectomy in the treatment of myasthenia gravis. Acta chir. scand. 107, 414 (1954).

    PubMed  CAS  Google Scholar 

  • Katz, B., and S. Thesleff: A study of the “desensitization” produced by acetylcholine at the motor endplate. J. Physiol. (Lond.) 138, 63 (1957).

    CAS  Google Scholar 

  • Keynes, G.: Investigation into thymic disease and tumor formation. Brit. J. Surg. 42, 449 (1955).

    Article  PubMed  CAS  Google Scholar 

  • Kuffler, S. W.: Specific excitability of the endplate region in normal and denervated muscle. J. Neurophysiol. 6, 99–110 (1943).

    CAS  Google Scholar 

  • Lammers, W., and D. Most van Spijk: Unsuccessful attempt to demonstrate a paralytic factor in serum of myasthenia gravis patients. Nature (Lond.) 173, 1192 (1954).

    Article  CAS  Google Scholar 

  • MacDermot, V.: The changes in the motor endplate in myasthenia gravis. Brain 83, 24–35 (1960).

    Article  PubMed  CAS  Google Scholar 

  • McSweyn, N. F., and H. Schwartz: Thymectomy in myasthenia gravis. Canad. med. Ass. J. 70, 311 (1954).

    CAS  Google Scholar 

  • Merrill, G. G.: Neostigmine toxicity: Report of fatality following diagnostic test for myasthenia. J. Amer. med. Ass. 137, 362 (1948).

    Article  CAS  Google Scholar 

  • Mertens, H. G.: Über den Verlauf der Myasthenie nach Carotissinus-denervierung. Nervenarzt 26, 150 (1955).

    PubMed  CAS  Google Scholar 

  • Nowell, P. T., and A. Wilson: Isolation of quaternary ammonium compounds from the extracts of thymus glands. In H. R. Viets, ed., Myasthenia Gravis: Second Internat. Sympos. Proc., 238–256. Springfield, Hl.: Chas. C. Thomas 1961.

    Google Scholar 

  • Osserman, K. E., E. S. Cohen and G. Genkins: Phospholine iodide: An anticholinesterase drug of new structure. Preliminary report in the treatment of myasthenia gravis. In H. R. Viets, ed., Myasthenia Gravis: Second Internat. Sympos. Proc., 581–594. Springfield, 111.: Chas. C. Thomas 1961.

    Google Scholar 

  • Osserman, K. E.,, and L. I. Kaplan: Studies in myasthenia gravis. Present status of therapy with octamethyl pyrophosphoramide (OMPA). Ann. intern. Med. 41, 108 (1954).

    Article  PubMed  CAS  Google Scholar 

  • Osserman, K. E., E. S. Cohen and G. Genkins: Studies in myasthenia gravis: Use of edrophonium chloride (Tensilon) in differentiating myasthenic from cholinergic weakness. Arch. Neurol. Psychiat. (Chicago) 70, 385 (1953).

    Article  CAS  Google Scholar 

  • Osserman, K. E., E. S. Cohen and G. Genkins: Rapid diagnostic test for myasthenia gravis: Increased muscle strength, without fasciculation, after intravenous administration of edrophonium (tensilon) chloride. J. Amer. med. Ass. 150, 265 (1952).

    Article  CAS  Google Scholar 

  • Osserman, K. E., P. Teng and L. I. Kaplan: Studies in myasthenia gravis. Preliminary report on therapy with Mestinon bromide. J. Amer. med. Ass. 155, 961 (1954).

    Article  CAS  Google Scholar 

  • Pateisky, K., E. Herzfelt and C. Stumpf: Der Effekt von Polymethylen-bis (N-methyl-carbaminolyl-m-Trimethylammoniumphenolen) BC 40, BC 47, BC 48 auf Cholinesterase-aktivat und Muskeltätigkeit bei Myasthenia gravis pseudoparalytica. Wien. klin. Wschr. 69, 2–7 (1957).

    CAS  Google Scholar 

  • Pateisky, K., O. Kraupp u. C. Stumpf: Klinische Erfahrungen mit Hexamethylen-bis-(N-methyl-carbaminoyl-m-trimethylammoniumphenol) (BC 40) bei Myasthenia gravis pseudoparalytica. Wien. klin. Wschr. 67, 578 (1955).

    CAS  Google Scholar 

  • Pelikan, E. W., J. E. Tether and K. R. Unna: Sensitivity of myasthenia gravis patients to tubocurarine and decamethonium. Neurology 3, 284 (1953).

    Article  PubMed  CAS  Google Scholar 

  • Randt, C. T.: Myasthenia gravis. Med. Clin. N. Amer. 37, 535 (1953).

    PubMed  CAS  Google Scholar 

  • Rider, J. A., S. Schulman, R. B. Richter, H. D. Moeller and K. P. DuBois: Treatment of myasthenia gravis with octamethyl pyrophosphoramide. J. Amer. med. Ass. 145, 967 to 972 (1951).

    Google Scholar 

  • Rowland, L. P., M. C. Korengold, I. A. Jaffe, L. Berg and G. M. Shy: Prostigmine induced muscle weakness in myasthenia gravis patients. Neurology 5, 89 (1955).

    Article  PubMed  CAS  Google Scholar 

  • Roe. J. H., R. J. Johns and D. Grob: Unpublished observations (1955).

    Google Scholar 

  • Safar, P.: Mouth-to-mouth airway. Anesthesiology 18, 904 (1957).

    Article  PubMed  CAS  Google Scholar 

  • Roe. J. H., Ventilatory efficacy of mouth-to-mouth artificial respiration. J. Amer. med. Ass. 167, 335–341 (1958).

    Google Scholar 

  • Roe. J. H., L. A. Escarrago and J. O. Elam: A comparison of the mouth-to-mouth and mouth-to-airwav methods of artificial respiration with the chest-pressure arm-lift methods. New Engl. J. Med. 258, 671–677 (1958).

    Google Scholar 

  • Schaumann, W., and C. Job: Differential effects of quaternary Cholinesterase inhibitor, phos-pholine, and its tertiary analogue, compound 217-AO, on central control of respiration and on neuromuscular transmission. The antagonism by 217-AO of the respiratory arrest caused by morphine. J. Pharmacol, exp. Ther. 123, 114–120 (1958).

    CAS  Google Scholar 

  • Schulman, S., J. A. Rider and R. B. Richter: Use of octamethyl pyrophosphoramide in the treatment of myasthenia gravis. J. Amer. med. Ass. 152, 1707 (1953).

    Article  CAS  Google Scholar 

  • Schwab, R. S.: WIN-8077 in the treatment of sixty myasthenia gravis patients. A twelve month report. Amer. J. Med. 19, 734 (1955).

    Article  PubMed  CAS  Google Scholar 

  • Schwab, R. S., and C. Leland: Sex and age in myasthenia gravis as critical factors in incidence and remission. J. Amer. med. Ass. 153, 1270 (1953).

    Article  CAS  Google Scholar 

  • Schwab, R. S., C. K. Marshall and W. T. Timberlake: WIN 8077 in treatment of myasthenia gravis, use of N,N’-bis (2-diethyl-aminoethyl) oxamide bis-2-chlorobenzyl chloride in 50 patients. J. Amer. med. Ass. 158, 625–628 (1955).

    Article  CAS  Google Scholar 

  • Schwab, R. S., K. E. Osserman and J. E. Tether: Treatment of myasthenia gravis. J. Amer. med. Ass. 165, 671–674 (1957).

    Article  CAS  Google Scholar 

  • Schwarz, H.: Urecholine in myasthenia gravis. Canad. med. Ass. J. 72, 346 (1955).

    CAS  Google Scholar 

  • Schwarz, H.: Curare-like factor in serum of myasthenia gravis patients. Canad. med. Ass. J. 67, 238 (1952).

    Google Scholar 

  • Seibert, P.: Zur Behandlung der Myasthenia gravis. Klinische Erfahrungen über die Behandlung der Myasthenia gravis pseudoparalytica mit Pyridostigmin. Dtsch. med. Wschr. 78, 805 (1953).

    Article  CAS  Google Scholar 

  • Simpson, J. A.: Discussion on myasthenia. The value of thymectomy. Proc. roy. Soc. Med. 49, 795 (1956).

    CAS  Google Scholar 

  • Simpson, J. A.: Myasthenia gravis: A new hypothesis. Scot. med. J. 5, 419–436 (1960).

    Google Scholar 

  • Strauss, A. J. L., B. C. Seegal, K. S. Hsu, P. M. Burkholder, W. L. Nastuk and K. E. Osserman: Immunofluorescence demonstration of a muscle binding complement-fixing serum globulin fraction in myasthenia gravis. Proc. Soc. exp. Biol. (N. Y.) 105, 184–191 (1960).

    Article  CAS  Google Scholar 

  • Tether, J. R.: Treatment of myasthenia gravis with mestinon bromide. J. Amer. med. Ass. 160, 156 (1956).

    Article  CAS  Google Scholar 

  • Tether, J. E.: Intravenous neostigmine in diagnosis of myasthenia gravis. Ann. intern. Med. 29, 1132 (1948).

    Article  PubMed  CAS  Google Scholar 

  • Thevenard, A.: Les effets de Innervation sin-carotidienne sur la myasthenia bulbospinal essai d’interprétation. Rev. neurol. 90, 107 (1954).

    PubMed  CAS  Google Scholar 

  • Torda, C., and H. G. Wolf: Depression of acetylcholine synthesis by serum from working muscle, healthy subjects and myasthenia gravis patients. Proc. Soc. exp. Biol. (N. Y.) 59, 13 (1945).

    Article  CAS  Google Scholar 

  • Tsukiyama, K., A. Nakai, R. Mine and T. Kitani: Studies on a myasthenic substance present in the serum of patient with myasthenic gravis. Med. J. Osaka Univ. 10, 159–170 (1959).

    CAS  Google Scholar 

  • Maanen, E. F.: Neuromuscular blocking agents. Amer. J. Med. 19, 669 (1955).

    Article  Google Scholar 

  • Viets, H. R.: Thymectomy for myasthenia gravis. J. Amer. med. Ass. 151, 1248 (1953).

    Google Scholar 

  • Viets, H. R.: Diagnosis of myasthenia gravis in patients with dysphagia. J. Amer. med. Ass. 134, 988 (1947).

    Google Scholar 

  • Viets, H. R., and R. S. Schwab: Prostigmin in the diagnosis of myasthenia gravis. New Engl. J. Med. 213, 1280 (1935).

    Google Scholar 

  • Westebb erg, M. R.: Clinical evaluation of ambenomium (Mysuran) chloride. Arch. Neurol. Psychiat. (Chicago) 75, 91 (1956).

    Article  Google Scholar 

  • Westebberg, M. R., and K. R. Magee: Treatment review. Myasthenia gravis. Neurology 5, 729 (1955).

    Google Scholar 

  • F. E. Shideman: Effect of 3-hydroxy phenyldimethylethylammonium chloride (Tensilon) in myasthenia gravis. Univ. Mich. med. Bull. 17, 311 (1951).

    PubMed  Google Scholar 

  • F. E. Shideman, and J. T. Lures: The clinical use of hexaethyltetraphosphate in myasthenia gravis. Univ. Mich. med. Bull. 14, 15 (1948).

    Google Scholar 

  • Wilson, A., G. A. Man and H. Georhegan: Cholinesterase activity of blood and muscle in myasthenia gravis. Quart. J. Med. 20, 13 (1951).

    CAS  Google Scholar 

  • Wilson. A., G. A., and H. B. Stoner: Myasthenia gravis. A consideration of its causation in a study of 14 cases. Quart. J. Med. 13, 1 (1944).

    Google Scholar 

  • Zaimis, E. J.: Motor endplate differences as a determining factor in the mode of action of neuromuscular blocking substances. J. Physiol. (Lond.) 122, 238 (1953).

    CAS  Google Scholar 

Download references

Authors
  1. David Grob
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Schools of Medicine, University of Pennsylvania, Philadelphia 4, Pa., USA

    George B. Koelle Ph.D., M.D. (Professor and Chairman) (Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 1963 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Grob, D. (1963). Therapy of Myasthenia Gravis. In: Koelle, G.B. (eds) Cholinesterases and Anticholinesterase Agents. Handbook of Experimental Pharmacology, vol 15. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-99875-1_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-99875-1_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-99877-5

  • Online ISBN: 978-3-642-99875-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation